NAGIOS: RODERIC FUNCIONANDO

In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication

dc.contributor.author	Giménez, Estela
dc.contributor.author	Guerreiro, Manuel
dc.contributor.author	Gozalbo Rovira, Roberto Vicente
dc.contributor.author	Aguilar, Cristóbal
dc.contributor.author	Albert, Eliseo
dc.contributor.author	Piñana, José Luis
dc.contributor.author	Solano Vercet, Carlos
dc.contributor.author	Navarro Ortega, David
dc.date.accessioned	2023-09-05T10:32:34Z
dc.date.available	2023-09-05T10:32:34Z
dc.date.issued	2023
dc.identifier.citation	Giménez, Estela Guerreiro, Manuel Gozalbo Rovira, Roberto Vicente Aguilar, Cristóbal Albert, Eliseo Piñana, José Luis Solano Vercet, Carlos Navarro Ortega, David 2023 In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication Revista Espanola de Quimioterapia
dc.identifier.uri	https://hdl.handle.net/10550/89071
dc.description.abstract	Introduction. Letermovir (LMV) is used for prophylaxis of cytomegalovirus (CMV) reactivation and end-organ disease in adult CMV-seropositive allogeneic hematopoietic stem cell transplant recipients (allo-HSCT). In turn, sirolimus (SLM) which displays in vitro anti-CMV activity, is frequently employed for prophylaxis of Graft vs. Host disease in allo-HSCT. Here, we aimed at assessing whether LMV and SLM used in combination may act synergistically in vitro on inhibiting CMV replication. Material and methods. The antiviral activity of LMV and SLM alone or in combination was evaluated by a checkerboard assay, using ARPE-19 cells infected with CMV strain BADrUL131-Y. LMV and SLM were used at concentrations ranging from 24 nM to 0.38 nM and 16 nM to 0.06 nM, respectively. Results. The mean EC50 for LMV and SLM was 2.44 nM (95% CI, 1.66-3.60) and 1.40 nM (95% CI, 0.41-4.74), respective. LMV and SLM interaction yielded mainly additive effects over the range of concentrations tested. Conclusion. The additive nature of the combination of LMV and SLM against CMV may have relevant clinical implications in management of CMV infection in allo-HSCT recipients undergoing prophylaxis with LMV.
dc.language.iso	eng
dc.relation.ispartof	Revista Espanola de Quimioterapia, 2023
dc.subject	Microbiologia
dc.subject	Patologia
dc.title	In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication
dc.type	journal article
dc.date.updated	2023-09-05T10:32:35Z
dc.identifier.doi	10.37201/req/016.2023
dc.identifier.idgrec	160985
dc.rights.accessRights	open access